HomeGeneticsGeneEIF2B1 gene
Back to Gene
EIF2B1 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

EIF2B1 gene

The EIF2B1 gene provides instructions for a subunit of a protein complex that regulates protein synthesis within the cell.

Normal Function

The EIF2B1 gene provides instructions for making one of five parts of a protein called eIF2B, specifically the alpha subunit of this protein. The eIF2B protein helps regulate overall protein production (synthesis) in the cell by interacting with another protein, eIF2. The eIF2 protein is called an initiation factor because it is involved in starting (initiating) protein synthesis.

Under some conditions, eIF2B increases protein synthesis by helping to recycle molecules called GTP, which carry energy to the initiation factor. Under other conditions, it slows protein synthesis by binding tightly to the initiation factor, which converts the eIF2B protein into an inactive form and prevents recycling of GTP. Proper regulation of protein synthesis is vital for ensuring that the correct levels of protein are available for the cell to cope with changing conditions.

Health Conditions Related to Genetic Changes

Leukoencephalopathy with vanishing white matter

Mutations in the EIF2B1 gene have been identified in a few people with leukoencephalopathy with vanishing white matter. These mutations cause partial loss of eIF2B function.

  • Impairment of eIF2B function makes it more difficult for the body's cells to regulate protein synthesis and deal with changing conditions and stress.
  • Researchers believe that cells in the white matter (nerve fibers covered by a fatty substance called myelin that insulates and protects nerves) may be particularly affected by an abnormal response to stress.
  • This abnormal stress response results in the signs and symptoms of leukoencephalopathy with vanishing white matter.

Frequently Asked Questions

EIF2B1 disease is inherited in an autosomal‑recessive manner. Both parents are typically carriers. Each subsequent pregnancy carries a 25 % chance of an affected child, a 50 % chance of a carrier, and a 25 % chance of an unaffected, non‑carrier child. Carrier testing for siblings and prenatal or pre‑implantation genetic diagnosis are options for families planning future pregnancies.
EIF2B1 encodes the alpha subunit of the eIF2B complex, which regulates protein synthesis during cellular stress. Mutations reduce eIF2B activity, impairing the brain’s ability to adapt to stress (e.g., fever, infections). This leads to loss of myelin‑producing cells and progressive white‑matter degeneration, manifesting as the “vanishing” appearance on MRI.
Yes. Febrile illnesses, head trauma, and even minor infections can precipitate acute neurological worsening because they increase cellular stress. Prompt treatment of fevers, avoidance of unnecessary vaccinations that cause high fevers, and rapid infection control are essential preventive strategies.
Currently, treatment is supportive—managing spasticity, seizures, and nutritional needs. Research is ongoing into agents that enhance eIF2B activity or reduce stress‑induced protein synthesis, but no FDA‑approved disease‑modifying drug exists yet. Families should discuss enrollment in clinical trials with a tertiary care center specializing in leukodystrophies.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab